These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

582 related articles for article (PubMed ID: 27222030)

  • 41. Platelet-lymphocyte ratio acts as an independent predictor of prognosis in patients with renal cell carcinoma.
    Wang Z; Peng S; Wang A; Xie H; Guo L; Jiang N; Niu Y
    Clin Chim Acta; 2018 May; 480():166-172. PubMed ID: 29462592
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era?
    Castle KO; Hoffman KE; Levy LB; Lee AK; Choi S; Nguyen QN; Frank SJ; Pugh TJ; McGuire SE; Kuban DA
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):693-9. PubMed ID: 22836052
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Peripheral Venous Blood Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Patients With Gastric Cancer Treated With SOX or XELOX Regimen Neoadjuvant Chemotherapy.
    Chen L; Hao Y; Cong X; Zou M; Li S; Zhu L; Song H; Xue Y
    Technol Cancer Res Treat; 2019 Jan; 18():1533033819829485. PubMed ID: 30760114
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Platelet to lymphocyte ratio as a novel prognostic tool for gallbladder carcinoma.
    Pang Q; Zhang LQ; Wang RT; Bi JB; Zhang JY; Qu K; Liu SS; Song SD; Xu XS; Wang ZX; Liu C
    World J Gastroenterol; 2015 Jun; 21(21):6675-83. PubMed ID: 26074706
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prostate-specific antigen kinetic profiles during androgen deprivation therapy as prognostic factors in castration-resistant prostate cancer.
    Kim M; Lee J; Jeong CW; Ku JH; Kim HH; Kwak C
    Urol Oncol; 2015 May; 33(5):203.e1-9. PubMed ID: 25726498
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Benign prostatic hyperplasia and prostate cancer differentiation via platelet to lymphocyte ratio.
    Kaynar M; Yildirim ME; Gul M; Kilic O; Ceylan K; Goktas S
    Cancer Biomark; 2015; 15(3):317-23. PubMed ID: 25586096
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preoperative Neutrophil-to-Lymphocyte Ratio is a Better Prognostic Serum Biomarker than Platelet-to-Lymphocyte Ratio in Patients Undergoing Resection for Nonmetastatic Colorectal Cancer.
    Choi WJ; Cleghorn MC; Jiang H; Jackson TD; Okrainec A; Quereshy FA
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S603-13. PubMed ID: 25900206
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Significant associations of prostate-specific antigen nadir and time to prostate-specific antigen nadir with survival in prostate cancer patients treated with androgen-deprivation therapy.
    Huang SP; Bao BY; Wu MT; Choueiri TK; Goggins WB; Liu CC; Huang CY; Pu YS; Yu CC; Wu TT; Huang CN; Huang CH; Wu WJ
    Aging Male; 2012 Mar; 15(1):34-41. PubMed ID: 21615239
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
    Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
    Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Predictive Value of the Platelet-To-Lymphocyte Ratio in Diagnosis of Prostate Cancer.
    Yuksel OH; Urkmez A; Akan S; Yldirim C; Verit A
    Asian Pac J Cancer Prev; 2015; 16(15):6407-12. PubMed ID: 26434851
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The preoperative platelet to lymphocyte ratio is a prognostic marker in patients with stage II colorectal cancer.
    Ozawa T; Ishihara S; Nishikawa T; Tanaka T; Tanaka J; Kiyomatsu T; Hata K; Kawai K; Nozawa H; Kazama S; Yamaguchi H; Sunami E; Kitayama J; Watanabe T
    Int J Colorectal Dis; 2015 Sep; 30(9):1165-71. PubMed ID: 26049902
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
    Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
    Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: cancer control and toxicity outcomes.
    Edelman S; Liauw SL; Rossi PJ; Cooper S; Jani AB
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1473-9. PubMed ID: 22245201
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A High Monocyte-to-Lymphocyte Ratio Predicts Poor Prognosis in Patients with Advanced Gallbladder Cancer Receiving Chemotherapy.
    Choi YH; Lee JW; Lee SH; Choi JH; Kang J; Lee BS; Paik WH; Ryu JK; Kim YT
    Cancer Epidemiol Biomarkers Prev; 2019 Jun; 28(6):1045-1051. PubMed ID: 30842131
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predictive Ability of Blood Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Gastrointestinal Stromal Tumors.
    Racz JM; Cleghorn MC; Jimenez MC; Atenafu EG; Jackson TD; Okrainec A; Venkat Raghavan L; Quereshy FA
    Ann Surg Oncol; 2015 Jul; 22(7):2343-50. PubMed ID: 25472648
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysis.
    Kishan AU; Wang X; Seiferheld W; Collette L; Sandler KA; Sandler HM; Bolla M; Maingon P; De Reijke T; Hanks GE; Nickols NG; Rettig M; Drakaki A; Reiter RE; Spratt DE; Kupelian PA; Steinberg ML; King CR
    JAMA Oncol; 2019 Jan; 5(1):91-96. PubMed ID: 30326032
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Whole pelvis radiotherapy for pathological node-positive prostate cancer : Oncological outcome and prognostic factors.
    Poelaert F; Fonteyne V; Ost P; De Troyer B; Decaestecker K; De Meerleer G; De Visschere P; Claeys T; Dhondt B; Lumen N
    Strahlenther Onkol; 2017 Jun; 193(6):444-451. PubMed ID: 28101585
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The prognostic effect of prostate-specific antigen half-life at the first follow-up visit in newly diagnosed metastatic prostate cancer.
    Kim KH; Han KS; Kim KH; Kim DK; Koo KC; Rha KH; Choi YD; Hong SJ
    Urol Oncol; 2015 Sep; 33(9):383.e17-22. PubMed ID: 26004165
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic value of preoperative plasma fibrinogen level and platelet-to-lymphocyte ratio (F-PLR) in patients with localized upper tract urothelial carcinoma.
    Huang J; Yuan Y; Wang Y; Zhang J; Kong W; Chen H; Chen Y; Huang Y
    Oncotarget; 2017 May; 8(22):36761-36771. PubMed ID: 27901490
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Platelet-to-lymphocyte ratio in peripheral blood: A novel independent prognostic factor in patients with melanoma.
    Qi Y; Zhang Y; Fu X; Wang A; Yang Y; Shang Y; Gao Q
    Int Immunopharmacol; 2018 Mar; 56():143-147. PubMed ID: 29414644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.